SS-31 (Elamipretide): Mitochondrial Protection, Cardioprotection, and Research Applications

SS-31 (elamipretide, Szeto-Schiller peptide 31, MTP-131) is a mitochondria-targeting tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH₂. Developed by Hazel Shen Szeto and Peter Schiller, it accumulates selectively in the inner mitochondrial membrane (IMM) where it binds cardiolipin — the phospholipid that anchors the electron transport chain complexes and governs mitochondrial cristae architecture. This mechanism underlies SS-31's cardioprotective, renoprotective, and anti-aging research applications.

Mechanism: Cardiolipin Binding and Cristae Restoration

SS-31's alternating charged/aromatic amino acid structure allows it to penetrate mitochondria independently of membrane potential — unlike many mitochondria-targeting compounds, it reaches the IMM even in depolarised or damaged mitochondria where membrane potential is lost. Once at the IMM, it:

• Stabilises cardiolipin: Cardiolipin organises electron transport chain (ETC) complexes into supercomplexes (respirasomes) and maintains cristae structure. SS-31 binding prevents cardiolipin peroxidation and fragmentation.
• Restores cristae architecture: Collapsed cristae — a hallmark of mitochondrial dysfunction — limit ETC efficiency. SS-31 restores cristae morphology, recovering respiratory capacity.
• Reduces ROS production: By maintaining ETC supercomplex organisation, SS-31 reduces electron leak and reactive oxygen species (ROS) production at Complex I and Complex III.
• Prevents cytochrome c release: Cardiolipin stabilisation reduces apoptotic signalling via the mitochondrial pathway.

Cardioprotection Research

SS-31's most extensively studied application is cardiac ischaemia-reperfusion injury. Key findings:

• Significant infarct size reduction in pre-clinical ischaemia-reperfusion models (30–50% reduction in infarct volume in multiple studies)
• Improved cardiac function recovery post-reperfusion (ejection fraction, diastolic function)
• Stealth BioTherapeutics conducted Phase 2 trials in heart failure with preserved ejection fraction (HFpEF) — the HFPEF trial
• Improvements in 6-minute walk test and exercise capacity in HFpEF patients
• Cardiac myocyte preservation during hypoxic stress

Renal Protection Data

Kidney tubular cells have the highest mitochondrial density of any tissue — making them particularly susceptible to mitochondrial dysfunction in acute kidney injury (AKI) and chronic kidney disease (CKD). SS-31 research in renal models shows:

• Reduced AKI severity in cisplatin and ischaemia-reperfusion renal injury models
• Protection of proximal tubular cell mitochondrial function
• Reduction in tubular cell apoptosis
• Improved GFR recovery post-AKI in preclinical models

Aging and Skeletal Muscle Research

Mitochondrial dysfunction is a central mechanism in sarcopenia and age-related muscle decline. SS-31 research in aged animal models demonstrates:

• Restoration of mitochondrial cristae morphology in aged skeletal muscle
• Improved maximal respiratory capacity (State 3 respiration)
• Reduced oxidative damage in muscle fibres
• Partial reversal of exercise intolerance in aged subjects

These findings position SS-31 as a research compound for both age-related muscle decline and exercise-induced oxidative damage in active populations.

Comparison to Other Mitochondrial Antioxidants

SS-31 differs mechanistically from other mitochondria-targeting antioxidants:

• vs MitoQ: MitoQ uses a ubiquinone moiety and positive charge for mitochondrial accumulation. SS-31 uses its aromatic-cationic structure to bind cardiolipin specifically — a more targeted mechanism than MitoQ's general antioxidant approach.
• vs CoQ10: CoQ10 supplementation replenishes mitochondrial electron carriers but does not restore cristae architecture. SS-31 addresses structural dysfunction that CoQ10 cannot remedy.

Frequently Asked Questions

Why can SS-31 reach mitochondria in damaged cells when other compounds cannot?

Most mitochondria-targeting strategies rely on membrane potential (ΔΨm) gradient to drive compound accumulation. SS-31's amphipathic, alternating charged/aromatic structure allows direct electrostatic interaction with cardiolipin without requiring membrane potential — critical for reaching mitochondria in injured cells where ΔΨm is reduced.

What is the primary administration route in preclinical research?

Subcutaneous or intravenous injection in animal models. The peptide has limited oral bioavailability due to GI proteolysis. Continuous subcutaneous infusion has been used in some chronic model studies.

References

• Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050.
• Daubert MA, et al. (2017). Novel Mitochondria-Targeting Peptide in Heart Failure Treatment. JACC: Heart Failure, 5(2), 149–157.
• Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261.